For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
57
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,404
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      TRIM25: A central factor in breast cancer

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          TRIM25 is emerging as a central factor in breast cancer due to its regulation and function. In particular, it has been shown that: (1) Estrogens modulate TRIM25 gene expression; (2) TRIM25 has activity as an E3-ligase enzyme for ubiquitin; and (3) TRIM25 is also an E3 ligase for interferon-stimulated gene 15 protein in the ISGylation system. Consequently, the proteome of mammary tissue is affected by TRIM25-associated pathways, involved in tumor development and metastasis. Here, we discuss the findings on the mechanisms involved in regulating TRIM25 expression and its functional relevance in breast cancer progression. These studies suggest that TRIM25 may be a biomarker and a therapeutic target for breast cancer.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          Ahmedin Jemal, Lindsey A Torre, Rebecca Siegel … (2018)
          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
          Article 0 comments Cited 28174 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

            A Goldhirsch, E P Winer, A S Coates … (2014)
            The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy. It refined its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a surrogate subtype classification, while noting that in those areas of the world where multi-gene molecular assays are readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions. Several multi-gene molecular assays were recognized as providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy. Cost and availability preclude their application in many environments at the present time. Broad treatment recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among more than 100 questions, only one (trastuzumab duration) commanded 100% agreement. The various recommendations in fact carried differing degrees of support, as reflected in the nuanced wording of the text below and in the votes recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints.
            Article 0 comments Cited 687 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ubiquitination in disease pathogenesis and treatment.

              Doris Popovic, Domagoj Vucic, Ivan Dikic (2014)
              Ubiquitination is crucial for a plethora of physiological processes, including cell survival and differentiation and innate and adaptive immunity. In recent years, considerable progress has been made in the understanding of the molecular action of ubiquitin in signaling pathways and how alterations in the ubiquitin system lead to the development of distinct human diseases. Here we describe the role of ubiquitination in the onset and progression of cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infection and muscle dystrophies. Moreover, we indicate how current knowledge could be exploited for the development of new clinical therapies.
              Article 0 comments Cited 502 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Angeles C Tecalco-Cruz
                María Jazmin Abraham-Juárez
                Helena Solleiro-Villavicencio
                Josué Orlando Ramírez-Jarquín
                Journal
                Journal ID (nlm-ta): World J Clin Oncol
                Journal ID (publisher-id): WJCO
                Title: World Journal of Clinical Oncology
                Publisher: Baishideng Publishing Group Inc
                ISSN (Electronic): 2218-4333
                Publication date (Print): 24 August 2021
                Publication date (Electronic): 24 August 2021
                Volume: 12
                Issue: 8
                Pages: 646-655
                Affiliations
                Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), Mexico 03100, Mexico. angeles.tecalco@ 123456uacm.edu.mx
                Laboratorio Nacional de Genómica para la Biodiversidad (LANGEBIO), Unidad de Genómica Avanzada, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Irapuato 36821, Mexico
                Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), Mexico 03100, Mexico
                Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico 04510, Mexico
                Author notes

                Author contributions: Tecalco-Cruz AC planned the study, participated in the research, organization of this article, and wrote the manuscript; Abraham–Juárez MJ, Solleiro–Villavicencio H and Ramírez-Jarquín JO participated in the research, wrote some part of the manuscript, and prepared some figures of this article.

                Corresponding author: Angeles C Tecalco-Cruz, PhD, Full Professor, Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), Colonia Del valle, San Lorenzo 290, Mexico 03100, Mexico. angeles.tecalco@ 123456uacm.edu.mx

                Article
                Other ID: jWJCO.v12.i8.pg646
                DOI: 10.5306/wjco.v12.i8.646
                PMC ID: 8394156
                PubMed ID: 34513598
                SO-VID: d85062d8-aec2-4df9-9ea3-c7b1a7bade53
                Copyright © ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
                License:

                This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

                History
                Date received : 1 February 2021
                Date revision received : 2 April 2021
                Date accepted : 27 July 2021
                Categories
                Subject: Minireviews

                Keywords: trim25,interferon-stimulated gene 15,ubiquitin,estrogens,breast cancer
                Data availability:
                Keywords: trim25, interferon-stimulated gene 15, ubiquitin, estrogens, breast cancer

                Comments

                Comment on this article

                scite_

                Similar content1,404

                See all similar

                Cited by3

                See all cited by

                Most referenced authors764

                See all reference authors